Sugi Predict

Sugi Predict / Compounds / SCHEMBL29412367

SCHEMBL29412367

SCHEMBL29412367

COCC1CCN1C(N)=O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 2/20 0.35
▸ PDK2 Q15119 1/20 0.35
▸ PDK3 Q15120 1/20 0.35
▸ HDAC8 Q9BY41 2/20 0.34
▸ HDAC6 Q9UBN7 2/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ DPP4 P27487 3/20 0.34
▸ DPP8 Q6V1X1 3/20 0.34
▸ POLB P06746 2/20 0.34
▸ ARG1 P05089 2/20 0.33
▸ ARG2 P78540 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ ROCK2 O75116 1/20 0.32
▸ ROCK1 Q13464 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ ADORA2A P29274 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27319486 1.00 PDK1 (0.35) PDK1PDK2PDK3HDAC8HDAC6
SCHEMBL2849479 0.89 POLB (0.43) HDAC8HDAC6HDAC1DPP4DPP8
SCHEMBL2843566 0.89 POLB (0.43) HDAC8HDAC6HDAC1DPP4DPP8
SCHEMBL5079416 0.89 POLB (0.43) HDAC8HDAC6HDAC1DPP4DPP8
SCHEMBL2571814 0.82 PDK1 (0.36) PDK1PDK2PDK3HDAC8HDAC6
SCHEMBL27038539 0.82 PDK1 (0.36) PDK1PDK2PDK3HDAC8HDAC6
SCHEMBL19687314 0.81 TSHR (0.44) PDK1PDK2PDK3HDAC8HDAC6
SCHEMBL13162310 0.78 PDK1 (0.61) PDK1PDK2PDK3
SCHEMBL25558007 0.77 POLB (0.34) PDK1PDK2PDK3HDAC8HDAC6
SCHEMBL2308749 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090104-A1 MODULATORS OF BETA CATENIN AND USES THEREOF DEWPOINT THERAPEUTICS, INC. (US) 2026-04-30 — — WO disclosed
US-12465643-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-11-11 — — US disclosed
US-20250319187-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2025-10-16 — — US disclosed
US-12409225-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-09 — — US disclosed
US-12403196-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-09-02 — — US disclosed
US-20250255964-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-08-14 — — US disclosed
US-20250242029-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2025-07-31 — — US disclosed
US-20250195662-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-06-19 — — US disclosed
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. 2025-06-19 — — US disclosed
US-20250186590-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-06-12 — — US disclosed
US-12280113-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-04-22 — — US disclosed
WO-2025045233-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 劲方医药科技(上海)股份有限公司 2025-03-06 — — WO disclosed
EP-4214209-A1 INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER Revolution Medicines, Inc. (US) 2023-07-26 — — EP disclosed
US-20230226186-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-20 — — US disclosed
EP-4208261-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. (US) 2023-07-12 — — EP disclosed
US-11690915-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2023-07-04 — — US disclosed
US-20220105185-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2022-04-07 — — US disclosed
WO-2022060836-A1 INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER Revolution Medicines, Inc. (US) 2022-03-24 — — WO disclosed
WO-2022060583-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. (US) 2022-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195662-A1 RAS INHIBITORS KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-20250186590-A1 RAS INHIBITORS KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-20250319187-A1 RAS INHIBITORS KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS SOS1, PPM1D, PTPN1 PDK1 3258/4885PDK2 4122/4885PDK3 4253/4885
US-20250255964-A1 RAS INHIBITORS KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-11690915-B2 Ras inhibitors KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-12403196-B2 Ras inhibitors KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-12465643-B2 Ras inhibitors KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-20230226186-A1 RAS INHIBITORS KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-20250242029-A1 RAS INHIBITORS KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-20220105185-A1 RAS INHIBITORS KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-12280113-B2 Ras inhibitors KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885
US-12409225-B2 Ras inhibitors KRAS, NRAS, HRAS PDK1 1486/4885PDK2 3129/4885PDK3 3068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.